Antitumor agent-207

• Description :

  Antitumor agent-207 is a Pt (IV) -NO prodrug with high lipid solubility, good stability, and excellent tumor targeted release ability. Antitumor agent-207 has significant anti proliferative activity in various cells such as TE-1 (IC50 = 1.79 μM), TE-10 (IC50 = 1.95 μM), KYSE-30 IC50 = 5.99 μM), KYSE-520 (IC50 = 5.53 μM) cells. Antitumor agent-207 can significantly enhance intracellular Pt accumulation and DNA platformization levels, and effectively release NO. Antitumor agent-207 can be used for research on cancers such as esophageal cancer[1].

• UNSPSC :

  12352005

• Target :

  Drug Metabolite

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Smiles :

  [O-]/[N+](N1CCN(C(CCC(O[Pt]([NH3])([NH3])(Cl)(Cl)OC(NCC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)=O)=O)=O)CC1)=N\OCC#C

• Molecular Formula :

  C26H32Cl2F3N7O7Pt

• Molecular Weight :

  877.56

• References & Citations :

  [1]Qian Z, et al. Lipophilic integrated bioorthogonal self-catalyzed nitric oxide donor-platinum (IV) prodrugs for enhanced antitumor efficacy against esophageal cancer. Eur J Med Chem. 2026 Jan 5;301:118221.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported